August 27, 2020 Strengthening viral safety evaluation business for biopharmaceuticals in Japan through business partnership with API Co., Ltd.
API Co., Ltd. (location of head office: 1-1 Kanohsakurada-cho, Gifu-shi), which is engaged in supportive business (CDMO) for the development and manufacture of biopharmaceuticals, and ViSpot Inc., which undertakes various viral safety evaluation tests as its main business, established a business partnership on August 27, 2020.
This partnership has enabled ViSpot to accept and assure the quality of the following essential tests in the combined development and manufacture of biopharmaceuticals.
[Provided by ViSpot]
- Viral clearance studies (GLP-compliant)
- Viral safety tests (GMP-compliant)
- Other virus tests
[Provided by API]
- Sterility tests (GMP-compliant)
- Mycoplasma safety tests (GMP-compliant)
- Endotoxin tests (GMP-compliant)
ViSpot will continue to enhance its viral safety evaluation testing services, thereby contributing to the development of biopharmaceuticals in Japan.
■About API Co., Ltd.
Founded in 1907. The company started to provide supportive business for beekeepers, and the manufacture and marketing of beekeeping appliances. At present, the company provides raw honey or products made of honey to the general public and corporations, while operating a wide variety of other businesses, including the contracted development and manufacture of pharmaceutical products, and the manufacture of reagents for research purposes.
■About ViSpot Inc.
Established in 2017 as a contract laboratory specializing in virus clearance studies (GLP-compliant) for biopharmaceutical production processes. Since 2020, a new series of viral safety tests (GMP-compliant) have been added to its range of services.